Tough Day for This Hepatitis C Underdog

It was a big day for investors watching the race to create the next generation of hepatitis C drug cocktails. Most of the major players released data for the European Association for the Study of the Liver conference today.

In the segment below, health-care analyst David Williamson explains why small-cap Achillion has an uphill battle in front of it while attempting to dethrone big pharma and big biotech Goliaths. Watch and find out how Achillion disappointed investors today, but its real test is still ahead.

What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: What's Really Eating at America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2381497, ~/Articles/ArticleHandler.aspx, 7/23/2014 12:48:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement